Blog - Page 4290 of 5592

MondayNov 03, 2008 3:54 am

Action Energy Inc. (TSX: AEC CN)

Action Energy Inc. (TSX: AEC CN), an Alberta-based emerging oil and natural gas exploration and production company, has an asset base that includes a mix of light oil, conventional heavy oil and natural gas-producing properties in west central Alberta, Peace River Arch, east central Alberta and southwest and southeast Saskatchewan. The properties offer extensive opportunities to add reserves and production at low cost and low risk. For further information, visit the Company's web site at www.action-energy.com.

MondayNov 03, 2008 3:53 am

Access Pharmaceuticals, Inc. (OTC BB: ACCP)

Access Pharmaceuticals, Inc. (OTC BB: ACCP), an emerging biopharmaceutical company, is committed to the development and commercialization of propriety products for the treatment and supportive care of cancer patients. Access' products currently include ProLindac(TM), the company’s lead oncology drug which is currently in Phase 2 clinical testing; and MuGard(TM), a viscous, mucoadhesive rinse for the management of patients with mucositis. For further information, visit the Company's web site at www.accesspharma.com.

MondayNov 03, 2008 3:53 am

L & L International Holdings, Inc. (OTC BB: LLFH)

L & L International Holdings, Inc. (OTC BB: LLFH) is a US public traded company that serves as a bridge connecting coal (energy) business between the US and China. While capitalizing on this market, L & L is continuing to make profit in the marketplace and friends in the environment. L & L is acquiring additional coal mines, and in the process, doing their part to improve the quality of air. For further information, visit the company website at: www.lnlinternational.com.

MondayNov 03, 2008 3:52 am

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company's web site at www.accentia.net.

SundayNov 02, 2008 9:10 am

Adherex Technologies, Inc. (AMEX: ADH)

Adherex Technologies, Inc. (AMEX: ADH), a biopharmaceutical company, is focused on discovering and developing novel cancer therapeutics. They currently have a number of products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Adherex’s mission is to become a leading developer of innovative treatments that address important unmet medical needs in cancer. For further information, visit the Company's web site at www.adherex.com.

SundayNov 02, 2008 9:09 am

Access Pharmaceuticals, Inc. (OTC BB: ACCP)

SundayNov 02, 2008 9:09 am

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)

SundayNov 02, 2008 9:08 am

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD)

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), a biopharmaceutical company, is focused on utilizing innovative technology to stimulate drug discovery and clinical development of novel treatments for central nervous system disorders. The company is currently developing a portfolio of its four most advanced product candidates, all of which originate from discoveries made using ACADIA’s proprietary drug discovery platform. For further information, visit the Company's web site at www.acadia-pharm.com.

SundayNov 02, 2008 9:04 am

Aastrom Biosciences, Inc. (NASDAQ: ASTM)

Aastrom Biosciences, Inc. (NASDAQ: ASTM) is focused on the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology utilizes a patient's own cells to create products to treat an array of chronic diseases as well as serious injuries. Currently, Aastrom is conducting a Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI trial). For further information, visit the Company's web site at www.aastrom.com.

SundayNov 02, 2008 9:03 am

A.P. Pharma, Inc. (NASDAQ: APPA)

A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, is committed to developing ethical (prescription) pharmaceuticals through the utilization of its proprietary polymer-based drug delivery systems. The Company's main focus is on developing and commercializing its bioerodible injectable and implantable systems under the trade name Biochronomer™. For further information, visit the Company's web site at www.appharma.com.

Site Search

Company Search

Action Energy Inc. (TSX: AEC CN)

Access Pharmaceuticals, Inc. (OTC BB: ACCP)

L & L International Holdings, Inc. (OTC BB: LLFH)

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)

Adherex Technologies, Inc. (AMEX: ADH)

Access Pharmaceuticals, Inc. (OTC BB: ACCP)

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD)

Aastrom Biosciences, Inc. (NASDAQ: ASTM)

A.P. Pharma, Inc. (NASDAQ: APPA)

Market Basics

Newsletter Publishers

Public Companies